Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977951> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4308977951 endingPage "vii82" @default.
- W4308977951 startingPage "vii81" @default.
- W4308977951 abstract "Abstract Disease relapse almost inevitably occurs in patients with adult-type diffuse glioma. Standard of care treatment options at tumor relapse are still not well defined. Few studies indicate that the combination of trofosfamide plus etoposide (T/E) may be feasible in pediatric glioblastoma patients. We collected clinicopathological data from adult patients with adult-type diffuse glioma treated with the combination of Trofosfamide (100mg/m2/day) and Etoposide (25mg/m2/day) for a minimum of four weeks at the Division of Clinical Neurooncology at the University Hospital Essen. T/E was administered orally in a “one week on, one week off” scheme. A cohort of patients receiving empiric treatment at the investigators’ discretion balanced for tumor entity and canonical prognostic factors served as control. We collected toxicity data as it pertained to CTCAE (Common Terminology Criteria for Adverse Events, version 5.0) and survival data to explore putative efficacy.A total of 33 patients were eligible for this analysis. In the IDH wild-type glioblastoma (n = 18) subgroup, median progression-free survival (3.8 months versus 2.9 months, HR: 2.09, 95% CI: 1.010-4.312, p = 0.0227; PFS-6: 39% versus 6%) and median overall survival (10.4 months versus 5.7 months, HR: 3.05, 95% CI: 1.393-6.655, p = 0.0008) were significantly prolonged as compared to the control cohort. In a multivariable Cox regression analysis, treatment with T/E emerged as statistically significant prognostic marker regarding progression-free survival and overall survival. We observed high-grade adverse events (CTCAE grade III or higher) in 21 (64%) of all recurrent glioma patients with hematotoxicity comprising most adverse events (n = 18, 86%; Lymphopenia: n=13, 62%). This study provides first indication that the combination of T/E is safe in patients with adult-type diffuse gliomas and may be associated with prolonged survival in adult patients with recurrent IDH wildtype glioblastoma. Our data provide a reasonable rationale for follow-up of a larger cohort in a prospective controlled trial." @default.
- W4308977951 created "2022-11-20" @default.
- W4308977951 creator A5001167896 @default.
- W4308977951 creator A5004075000 @default.
- W4308977951 creator A5023401842 @default.
- W4308977951 creator A5026784314 @default.
- W4308977951 creator A5031780975 @default.
- W4308977951 creator A5036062977 @default.
- W4308977951 creator A5041144526 @default.
- W4308977951 creator A5043495754 @default.
- W4308977951 creator A5050699846 @default.
- W4308977951 creator A5051467826 @default.
- W4308977951 creator A5052523213 @default.
- W4308977951 creator A5071494218 @default.
- W4308977951 creator A5074474133 @default.
- W4308977951 creator A5074697803 @default.
- W4308977951 creator A5088964414 @default.
- W4308977951 date "2022-11-01" @default.
- W4308977951 modified "2023-09-25" @default.
- W4308977951 title "CTNI-43. COMBINATION OF TROFOSFAMIDE PLUS ETOPOSIDE IN RECURRENT ADULT-TYPE DIFFUSE GLIOMAS" @default.
- W4308977951 doi "https://doi.org/10.1093/neuonc/noac209.308" @default.
- W4308977951 hasPublicationYear "2022" @default.
- W4308977951 type Work @default.
- W4308977951 citedByCount "0" @default.
- W4308977951 crossrefType "journal-article" @default.
- W4308977951 hasAuthorship W4308977951A5001167896 @default.
- W4308977951 hasAuthorship W4308977951A5004075000 @default.
- W4308977951 hasAuthorship W4308977951A5023401842 @default.
- W4308977951 hasAuthorship W4308977951A5026784314 @default.
- W4308977951 hasAuthorship W4308977951A5031780975 @default.
- W4308977951 hasAuthorship W4308977951A5036062977 @default.
- W4308977951 hasAuthorship W4308977951A5041144526 @default.
- W4308977951 hasAuthorship W4308977951A5043495754 @default.
- W4308977951 hasAuthorship W4308977951A5050699846 @default.
- W4308977951 hasAuthorship W4308977951A5051467826 @default.
- W4308977951 hasAuthorship W4308977951A5052523213 @default.
- W4308977951 hasAuthorship W4308977951A5071494218 @default.
- W4308977951 hasAuthorship W4308977951A5074474133 @default.
- W4308977951 hasAuthorship W4308977951A5074697803 @default.
- W4308977951 hasAuthorship W4308977951A5088964414 @default.
- W4308977951 hasBestOaLocation W43089779511 @default.
- W4308977951 hasConcept C126322002 @default.
- W4308977951 hasConcept C141071460 @default.
- W4308977951 hasConcept C143998085 @default.
- W4308977951 hasConcept C197934379 @default.
- W4308977951 hasConcept C2776694085 @default.
- W4308977951 hasConcept C2777793932 @default.
- W4308977951 hasConcept C2778119113 @default.
- W4308977951 hasConcept C2778227246 @default.
- W4308977951 hasConcept C2780739268 @default.
- W4308977951 hasConcept C502942594 @default.
- W4308977951 hasConcept C50382708 @default.
- W4308977951 hasConcept C71924100 @default.
- W4308977951 hasConcept C72563966 @default.
- W4308977951 hasConceptScore W4308977951C126322002 @default.
- W4308977951 hasConceptScore W4308977951C141071460 @default.
- W4308977951 hasConceptScore W4308977951C143998085 @default.
- W4308977951 hasConceptScore W4308977951C197934379 @default.
- W4308977951 hasConceptScore W4308977951C2776694085 @default.
- W4308977951 hasConceptScore W4308977951C2777793932 @default.
- W4308977951 hasConceptScore W4308977951C2778119113 @default.
- W4308977951 hasConceptScore W4308977951C2778227246 @default.
- W4308977951 hasConceptScore W4308977951C2780739268 @default.
- W4308977951 hasConceptScore W4308977951C502942594 @default.
- W4308977951 hasConceptScore W4308977951C50382708 @default.
- W4308977951 hasConceptScore W4308977951C71924100 @default.
- W4308977951 hasConceptScore W4308977951C72563966 @default.
- W4308977951 hasIssue "Supplement_7" @default.
- W4308977951 hasLocation W43089779511 @default.
- W4308977951 hasOpenAccess W4308977951 @default.
- W4308977951 hasPrimaryLocation W43089779511 @default.
- W4308977951 hasRelatedWork W1411054225 @default.
- W4308977951 hasRelatedWork W2111314921 @default.
- W4308977951 hasRelatedWork W2761925198 @default.
- W4308977951 hasRelatedWork W3009255790 @default.
- W4308977951 hasRelatedWork W3104817578 @default.
- W4308977951 hasRelatedWork W4299458342 @default.
- W4308977951 hasRelatedWork W4304808194 @default.
- W4308977951 hasRelatedWork W4309244132 @default.
- W4308977951 hasRelatedWork W4311192294 @default.
- W4308977951 hasRelatedWork W4366351644 @default.
- W4308977951 hasVolume "24" @default.
- W4308977951 isParatext "false" @default.
- W4308977951 isRetracted "false" @default.
- W4308977951 workType "article" @default.